Revolo fast-tracks oral drug for allergic diseases after promising results The company’s peptide therapy, '1104, shows promise as an oral treatment for allergic diseases, with clinical trials expected to begin in 2026.

Revolo Biotherapeutics is accelerating development of its oral allergy drug, ‘1104. Clinical trials start in 2026. 💊

#News #Biotech #AllergyTreatment #Immunotherapy #ClinicalTrials #EosinophilicEsophagitis #AtopicDermatitis #Revolo1104 #HealthcareInnovation #DrugDevelopment #Biopharma

Revolo fast-tracks oral drug for allergic diseases after promising results The company’s peptide therapy, '1104, shows promise as an oral treatment for allergic diseases, with clinical trials expected to begin in 2026.

Revolo Biotherapeutics is accelerating development of its oral allergy drug, ‘1104. Clinical trials start in 2026. 💊

#News #Biotech #AllergyTreatment #Immunotherapy #ClinicalTrials #EosinophilicEsophagitis #AtopicDermatitis #Revolo1104 #HealthcareInnovation #DrugDevelopment #Biopharma